Yong Bai stands out among peers in the Chinese market thanks to his expert handling of competition matters across a range of sectors from energy to life sciences.
Yong Bai is partner in Clifford Chance's antitrust practice in mainland China. Before joining the firm, he worked for the Ministry of Commerce of the People's Republic of China (MOFCOM). He is a member of the firm's healthcare and life sciences group, consumer goods and retail group and telecommunications, media and technology group.
Yong Bai has unrivalled experience and knowledge of the competition law landscape within China, based on his prior experience working within MOFCOM, followed by over 10 years’ experience advising domestic and multinational corporations on antitrust and regulatory matters. He is familiar with the working practices of the various antitrust enforcement authorities in China. In addition, over the past couple of years Yong Bai has also worked in the firm's London and Brussels offices, where he gained first-hand experience of the practice of competition law in these jurisdictions. As a result, Yong Bai is one of the very few lawyers in the market able to give Chinese clients advice on global competition law issues from a Chinese perspective.
Yong Bai covers a wide range of work and industry types, including high-profile global deals such as Pfizer's US$160 billion merger with Allergan and GE's US$32 billion merger of its oil and gas business with Baker Hughes; inbound investment into China for multinational corporations such as Coca-Cola and PE funds such as CVC; outbound deals by Chinese investors, such as COFCO's acquisitions of Noble Agri and Nidera which involved approximately 30 filings across multiple jurisdictions; antitrust investigations and leniency applications for clients in the pharmaceutical, logistics and auto parts sectors; as well as compliance and regulatory work for regional and global clients.
Yong Bai frequently participates in conferences and initiatives alongside academics and officials. He is member of the translation committee of The Economic Assessment of Mergers under European Competition Law (Cambridge University Press and Law Press China, 2017). He is co-author of the chapter on antitrust and the pharmaceutical sector in China Antitrust Law Journal (2017), and a chapter on Chinese companies' navigation of outbound investment, in China's Anti-Monopoly Law – The First Five Years (Wolters Kluwer, 2013). He is also a member of the Clifford Chance team appointed by MOFCOM to advise on the rules and form for the simplified review mechanism.
Yong Bai has been recognised by Chambers Asia-Pacific as an "associate to watch" (2012 to 2015), as "up and coming" (2016 to 2018) and as a leading ranked lawyer (2019). Feedback reflects that he "is very well known in the mainland", "can connect locally and give us that localised advice", "regularly assists on high-stakes antitrust matters", "won plaudits for his deep knowledge of Chinese regulations and his robust MOMFCOM experience", "is deemed key for handling high-profile transactions at a day-to-day level", "offers expertise gained in London and Brussels and is especially valued by clients and peers for his knowledge of MOFCOM procedures", "praised for his deep understanding of China's antitrust enforcement regime and broad knowledge about the markets", and "business-driven mindset and profound knowledge of antitrust law." In addition, Yong Bai was awarded "competition – rising star" by China Law and Practice in 2014.